Surmodics, Inc. (SRDX): Price and Financial Metrics

Surmodics, Inc. (SRDX): $42.00

0.08 (+0.19%)

POWR Rating

Component Grades

Momentum

C

Stability

C

Sentiment

Quality

A

SRDX Price/Volume Stats

Current price $42.00 52-week high $42.36
Prev. close $41.92 52-week low $24.56
Day low $41.79 Volume 221,100
Day high $42.01 Avg. volume 128,495
50-day MA $32.95 Dividend yield N/A
200-day MA $32.71 Market Cap 598.92M

SRDX Stock Price Chart Interactive Chart >


Surmodics, Inc. (SRDX) Company Bio


SurModics Inc. provides surface modification and in vitro diagnostic technologies to the healthcare industry. The company operates through two segments, Medical Device and In Vitro Diagnostics. The company was founded in 1979 and is based in Eden Prairie, Minnesota.


SRDX Latest News Stream


Event/Time News Detail
Loading, please wait...

SRDX Latest Social Stream


Loading social stream, please wait...

View Full SRDX Social Stream

Latest SRDX News From Around the Web

Below are the latest news stories about SURMODICS INC that investors may wish to consider to help them evaluate SRDX as an investment opportunity.

SurModics (SRDX) Soars 6.2%: Is Further Upside Left in the Stock?

SurModics (SRDX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Yahoo | December 14, 2023

Here's Why You Should Retain Surmodics (SRDX) Stock for Now

Surmodics' (SRDX) solid prospects in the thrombectomy business raise optimism about the stock.

Yahoo | December 12, 2023

Surmodics Announces TRANSCEND Trial 36-Month Data Presented at 50th Annual VEITH Symposium

EDEN PRAIRIE, Minn., November 16, 2023--Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that 36-month data from its TRANSCEND clinical trial was presented by Dr. Peter A. Schneider at the 50th Annual VEITH Symposium in New York, New York.

Yahoo | November 16, 2023

Surmodics Announces 24-Month Data from the SWING Trial Presented at VEITHsymposium

EDEN PRAIRIE, Minn., November 16, 2023--Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, announced today that 24-month data from the SWING Trial, a first-in-human study of the safety and performance of the Sundance™ Sirolimus Drug-Coated Balloon (DCB) was presented at the 50th annual VEITH Symposium in New York, New York.

Yahoo | November 16, 2023

Surmodics, Inc.'s (NASDAQ:SRDX) Intrinsic Value Is Potentially 91% Above Its Share Price

Key Insights Using the 2 Stage Free Cash Flow to Equity, Surmodics fair value estimate is US$66.09 Surmodics' US$34.64...

Yahoo | November 15, 2023

Read More 'SRDX' Stories Here

SRDX Price Returns

1-mo 25.15%
3-mo 49.09%
6-mo 11.26%
1-year 65.16%
3-year -21.05%
5-year 1.60%
YTD 15.54%
2023 6.54%
2022 -29.14%
2021 10.64%
2020 5.04%
2019 -12.34%

Continue Researching SRDX

Here are a few links from around the web to help you further your research on Surmodics Inc's stock as an investment opportunity:

Surmodics Inc (SRDX) Stock Price | Nasdaq
Surmodics Inc (SRDX) Stock Quote, History and News - Yahoo Finance
Surmodics Inc (SRDX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!